Regulatory

FDA's top official disclosed Thursday his agency is considering whether it should pursue the issuance of a regulation that would authorize the use of CBD in foods and dietary supplements.

The Farm Bill did much to liberate hemp and CBD–but not everything it could have. The FDA still has regulatory authority here. That is, if they choose to wield it.

FDA’s top official on Wednesday announced a new working group within his agency to improve oversight of the dietary supplement industry.

The bill passes both the Senate and U.S. House of Representatives, and is expected to be signed into law by the president in the coming week.

Harbin Pharmaceutical plans to invest $300 million, but it’s not clear when the deal will close.

The July 31 warning letter reflects FDA's continuing concern over the marketing of CBD products—including supplements—to treat diseases like cancer and schizophrenia without agency drug approval.